骨重塑是一个动态、持续的过程，包括两个阶段：破骨细胞作用下骨的吸收、迁移和成骨细胞作用下新骨的合成，一旦此平衡失调，就会导致严重的骨代谢疾病。目前临床中已广泛应用的抗骨质疏松药物存在一个共性问题，即抑制骨吸收的同时也抑制了新骨的形成。而Semaphorin3A作为成骨细胞产生的一种分泌型蛋白，抑制骨吸收的同时促进了新骨的再生，在骨质疏松的治疗方面具有双向调节作用，为骨质疏松的治疗提供了新视野。本文就Semaphorin3A在抗骨质疏松作用靶点上的相关分子机制研究进展作一综述。%Bone remodeling is a dynamic and continuous process which consists of two phases:the absorption and removal of bone by osteoclasts and the formation of new bone by osteoblasts and the imbalance of this can cause severe skeletal disorders. The aiti -osteoporosis drugs used commonly in clinic nowadays have a general problem:it inhibits not only bone absorption,but also bone formation as well. Recent studies have shown that Semaphorin3A,a secreted protein produced by osteoblasts,can inhabit bone absorption and at the same time promote bone formation,and therefore produce a new class of dual-action therapeutic agent for osteoporosis and a new perspective of treatment against osteoporosis. This article briefly reviews the research progress of molecular mechanism of Semaphorin3A targeting on anti-osteoporosis.
展开▼
